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CLINICAL TRIALS AND OBSERVATIONS
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Although imatinib, a BCR-ABL tyrosine
kinase inhibitor, is used to treat acute
Philadelphia chromosome–positive (Ph)
leukemia, it does not prevent central ner-
vous system (CNS) relapses resulting
from poor drug penetration through the
blood-brain barrier. Imatinib and dasa-
tinib (a dual-specific SRC/BCR-ABL ki-
nase inhibitor) were compared in a pre-
clinical mouse model of intracranial Ph
leukemia. Clinical dasatinib treatment in
patients with CNS Ph leukemia was as-
sessed. In preclinical studies, dasatinib
increased survival, whereas imatinib
failed to inhibit intracranial tumor growth.
Stabilization and regression of CNS dis-
ease were achieved with continued dasa-
tinib administration. The drug also demon-
strated substantial activity in 11 adult and
pediatric patients with CNS Ph leuke-
mia. Eleven evaluable patients had clini-
cally significant, long-lasting responses,
which were complete in 7 patients. In
3 additional patients, isolated CNS re-
lapse occurred during dasatinib therapy;
and in 2 of them, it was caused by expan-
sion of a BCR-ABL–mutated dasatinib-
resistant clone, implying selection pres-
sure exerted by the compound in the
CNS. Dasatinib has promising therapeu-
tic potential in managing intracranial leu-
kemic disease and substantial clinical
activity in patients who experience CNS
relapse while on imatinib therapy. This
study is registered at ClinicalTrials.
gov as CA180006 (#NCT00108719) and
CA180015 (#NCT00110097). (Blood. 2008;
112:1005-1012)
Introduction
Central nervous system (CNS) involvement is a relatively common
complication in Philadelphia chromosome (Ph)–positive acute
lymphoblastic leukemia (PhALL) and blast crisis-chronic myelog-
enous leukemia (BC-CML).1 Imatinib is a first-generation BCR-
ABL tyrosine kinase inhibitor, which is approved for use in patients
with Ph leukemias. Despite its use, up to 20% of imatinib-treated
patients with either lymphoid or myeloid BC-CML or Ph ALL
develop CNS relapses.1,2 In many cases, these have occurred
despite complete responses in peripheral blood and bone marrow2-4
and are attributable to poor penetration of imatinib into the
cerebrospinal fluid (CSF) with inadequate concentrations for
kinase inhibition.5 This may be, at least partly, because imatinib is a
substrate for the drug-eluting P-glycoprotein, which results in
subtherapeutic levels of imatinib in the CNS.1,5-8
Conventional therapy for CNS leukemia, including intrathecal
chemotherapy, high-dose systemic chemotherapy (cytarabine,
methotrexate), and radiotherapy, is unsatisfactory as many patients
experience significant toxicity, short-lived responses, and ulti-
mately death resulting from refractory leukemia.9
Dasatinib, a second-generation inhibitor of tyrosine kinases
SRC and BCR-ABL, has shown significant activity in adults
with imatinib-resistant or -intolerant CML or Ph ALL.10-14 In
vitro, dasatinib has 325-fold greater potency than imatinib for
inhibiting BCR-ABL.15 It effectively inhibits the growth of
leukemic clones harboring all known imatinib-resistant BCR-
ABL kinase domain point mutations, with the exception of
V299L, T315I, and F317L.16 Dasatinib also has antileukemic
activity in the multidrug-resistant K562/ADM model that highly
expresses the P-glycoprotein drug efflux pump.17 A recent single
case report suggested regression of Ph CNS leukemia after
dasatinib therapy.18
Based on these results, we further investigated the preclinical
and clinical effects of dasatinib in CNS leukemia. We show that
dasatinib is associated with increased survival in a mouse model of
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intracranial CML and induces clinically meaningful responses in
patients with CNS disease.
Methods
Preclinical analysis of dasatinib in an animal model of
intracranial CML
Compounds, tumor cell lines, and reagents. Dasatinib (synthesized by
Bristol-Myers Squibb, Princeton, NJ) and commercially available imatinib
(Novartis, Basel, Switzerland) were dissolved at 10 mM in 100% dimethyl
sulfoxide (DMSO). In the in vitro experiments, compounds were diluted
with culture medium to yield final concentrations of less than or equal to
0.1% DMSO. Sterile buffers and solutions were obtained from Invitrogen
(Carlsbad, CA). Sterile tissue culture ware was obtained from Fisher
Scientific (Pittsburgh, PA). K562 CML cells were obtained from ATCC
(Manassas, VA) and maintained in fetal bovine serum (Invitrogen).
Study protocols were approved by the Institutional Review Board/
Independent Ethics Committee at each participating center.
In vitro cell proliferation assay. K562 CML cells were seeded at
105 cells/mL in regular culture medium into 6-well plates, and different
concentrations of compound (or DMSO for controls) were added. At 24, 48,
and 72 hours after treatment, cells were harvested and total viable cell
counts were determined using the ViCell cell viability analyzer (Beckman
Coulter, Fullerton, CA).
Transfection of K562 cells with luciferase construct. The firefly
luciferase (luc) gene was subcloned from pGL3 (Promega, Madison, WI)
into the pcDNA6.2 expression vector (Invitrogen). Transfection of the
K562 cell line was performed using Lipofectamine 2000 reagent (Invitro-
gen), and cells were selected with 10 g/mL Blasticidin (Invitrogen) for
2 weeks. Single colonies were cloned using a soft agar colony formation
assay. Individual clones were then screened for bioluminescence using an in
vitro luciferase assay (LucLite, PerkinElmer Life and Analytical Sciences,
Waltham, MA). Bioluminescence of individual clones was verified in vitro
using the IVIS Imaging System (Xenogen, Alameda, CA). Initially,
15 antibiotic-resistant clones were isolated from the soft agar assay. Clone
K562-pLUC#2 (Figure S1, available on the Blood website; see the
Supplemental Materials link at the top of the online article) was eventually
selected for use because it exhibited the following desirable characteristics:
stable luminescence expression, sensitivity to BCR-ABL inhibitors compa-
rable with the parental K562 cells, and high in vivo tumorigenicity.
Animals. Female severe combined immunodeficient (SCID)–beige
mice, 5 to 6 weeks of age, were obtained from Harlan (Indianapolis, IN) and
maintained in an ammonia-free environment in a defined and pathogen-free
colony. They were fed food and water ad libitum. All studies were
performed in accordance with the American Association for Accreditation
of Laboratory Animal Care.
Tumor model and compound administration. Before leukemic cell
implantation, animals were anesthetized using Avertin (Sigma-Aldrich,
St Louis, MO) administered intraperitoneally, at a dose of 250 mg/kg.
K562 cells or bioluminescent K562-pLUC#2 cells (2  106 cells/
mouse) were then injected intracranially in a total volume of 0.02 mL
into SCID-beige mice.
Five to 9 days after cell implantation, mice were randomized into
treatment and control groups, and treatment was initiated. Dasatinib was
formulated in propylene glycol:water (1:1). Imatinib was formulated in 5%
carboxymethylcellulose solution. Both compounds were administered
orally in a volume of 0.01 mL/g of mouse body weight.
Antitumor activity was evaluated in terms of (1) increases in lifespan
reflected by the prolongation of median survival time (MST) and expressed
as %T/C value (ie, the ratio of MST of treated vs control groups); and
(2) inhibition of tumor growth as determined by bioluminescence imaging
(BLI). Activity was defined as a statistically significant increase in lifespan
corresponding to a T/C more than or equal to 125%.
Statistical analysis. Statistical significance for survival and tumor
growth in the preclinical studies was determined by the Gehan generalized
Wilcoxon test and required a P value less than .05.
Bioluminescence imaging. Bioluminescence signals were analyzed
using Living Image software (Caliper Life Sciences, Hopkinton, MA). For
in vitro imaging, bioluminescent cells at various concentrations were
incubated at 37°C with D-luciferin (Xenogen) at 150 g/mL for 7 to
10 minutes before imaging for 2 minutes. For in vivo imaging, mice were
given an intraperitoneal dose of 150 mg/kg of D-luciferin immediately
before being anesthetized with Avertin (250 mg/kg) and were imaged
15 minutes later using the IVIS Imaging System 100 Series (Xenogen).
Quantitation was based on total flux (photons/sec) of emitted light as a
measure of the relative number of viable tumor cells. Data were analyzed
using Xenogen Living Image software.
Dasatinib plasma and brain pharmacokinetics in mice. Plasma and
brain dasatinib concentrations were determined by high performance liquid
chromatography/mass spectroscopy (HPLC/MS). The analytical equipment used
consisted of a Hewlett Packard (Palo Alto, CA) model 1100 HPLC/Autosampler
combination, coupled to a Phenomenex Prodigy C18-ODS3 column. A gradient
elution method was used with a mobile phase consisted of 5 mM of ammonium
acetate in a mix of water/acetonitrile, pH 5.0. The HPLC was interfaced to a
Finnigan LCQ Advantage ion-trap mass spectrometer (Thermo Fisher Scientif-
ics, Waltham, MA) operated in the positive ion electrospray, full MS/MS mode.
For dasatinib, fragmentation of m/z 488 yielded daughter ions for quantitation at
m/z 401. For the internal standard, m/z 444 was fragmented to yield daughters at
m/z 303. Helium was the collision gas. The standard curve ranged from 2.7 nM to
40M and was fitted with a quadratic regression weighted by reciprocal
concentration (1/x). The limit of quantitation was 2.7 nM. Plasma samples
(50L) were deproteinized before analysis with 3 volumes of acetonitrile
containing 5g/mL BMS-354990 as internal standard. Brain samples were
homogenized in 2 parts water before dilution in acetonitrile. Plasma/brain
ratios were calculated to assess the relative ability of dasatinib to cross the
blood-brain barrier.
Clinical analysis of dasatinib in CNS Ph leukemia
Patients. Patients with Ph ALL or BC-CML and CNS involvement who
received treatment with dasatinib, either as part of clinical trials evaluating
dasatinib in PhALL or BC-CML or on a “compassionate-use” basis, were
identified. None of the patients was using dasatinib at the time of CNS
disease diagnosis, with the exception of a subgroup of the 3 patients who
developed CNS disease relapse while on dasatinib therapy. Informed
consent was obtained from all patients taking part in clinical trials in
accordance with the Declaration of Helsinki.
Treatment. Adult patients received oral dasatinib 140 mg once daily or
70 mg twice daily. The dasatinib dose could be adjusted after one cycle of
treatment (4 weeks), with dose escalation in patients with lack of response
and dose reduction in patients with unacceptable toxicity. Pediatric and
adolescent patients with Ph ALL treated according to study protocol
received oral dasatinib 60 to 160 mg/m2 once daily. Dasatinib was
administered until disease progression, intolerable toxicity, withdrawal of
consent, or until the investigator and patient agreed that discontinuation of
therapy was in the best interest of the patient.
Patient evaluation. Lumbar punctures were performed every 1 to
4 weeks until resolution to follow outcome. Responses were classified
according to criteria described by Odom et al.19 Briefly, a complete
response was defined by an absence of blasts in the CSF, a very good partial
response as a CSF mononuclear cell count less than 5 106/L and
identification of only single blasts on cytospin slide examination, and a
partial response as a decrease in CSF mononuclear cell count by more than
50%. Response duration was measured from the first day the response
criteria were met until the date treatment was discontinued because of
progression or death, or the date of the last CNS assessment. Dasatinib and
dasatinib metabolite concentrations within the CSF were measured by
HPLC/MS/MS chromatography.
Analysis of BCR-ABL gene mutations in CSF. The total RNA from
CSF cell samples was extracted using RNeasy Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. Because of the
small number of cells resulting in low RNA yields, the samples were
subjected to RNA amplification with Agilent Low RNA Input Fluorescent
Linear Amplification Kit (Agilent Technologies, Palo Alto, CA). The
amplified cRNA was then purified and further reverse-transcribed to cDNA
1006 PORKKA et al BLOOD, 15 AUGUST 2008  VOLUME 112, NUMBER 4
 For personal use only. at Erasmus MC Medical Library on May 20, 2009. www.bloodjournal.orgFrom 
according to published recommendations of Europe Against Cancer pro-
gram.20 Polymerase chain reactions (PCRs) were performed as described
with minor modifications.21,22 The amplified PCR products were then
sequenced with direct sequencing and ABI Prism 3100 Genetic Analyzer
(Applied Biosystems, Foster City, CA).
Results
Antitumor effects of dasatinib and imatinib in mice
Experiment 1. We initially evaluated the efficacy of dasatinib and
imatinib in the K562 intracranial CML tumor model. Drugs were
administered orally starting on day 5 after tumor implantation, and
treatment was continued until clear disease progression was observed
(ie, MST was achieved for each individual treatment set). Dasatinib was
administered using a 5-days-on/2-days-off twice-daily schedule (Mon-
day through Friday) at dose levels of 5 mg/kg and 15 mg/kg, whereas
imatinib was administered continuously twice daily (without drug
administration break period) at a dose level of 100 mg/kg. Dasatinib was
associated with a dose-dependent increase in survival compared with
control groups (P .01; Table 1). In contrast, imatinib completely failed
to increase the MST.
Experiment 2. We next assessed the antitumor activity of
dasatinib and imatinib in the intracranial CML tumor model in
more detail. A K562 variant cell line was generated (K562-
pLUC#2) overexpressing the firefly luciferase gene to allow
noninvasive monitoring of intracranial tumor growth in vivo using
BLI. K562-pLUC#2 cells were injected intracranially into SCID-
beige mice, and the mice treated on day 6 after tumor implantation
for 14 days with either dasatinib 15 mg/kg or imatinib 100 mg/kg
using the same schedules described previously. Tumor growth was
measured on day 5 (pretreatment) and once weekly thereafter by
BLI until animals became moribund. Bioluminescence in the
untreated and imatinib groups continued to increase over time. In
contrast, dasatinib-treated animals displayed a striking inhibition of
tumor growth between pretreatment and end-of-drug treatment
time points. Moreover, several animals showed regression of large
primary tumors, as indicated by a decrease in bioluminescence
signal (data not shown). Quantitative analysis of the mean photons
emitted from the intracranial K562-pLUC#2 tumors over time is
shown in Figure 1A. Tumor bioluminescence increased signifi-
cantly in the untreated control group. Imatinib treatment failed to
inhibit intracranial K562-pLUC#2 tumor growth, with results
comparable with untreated controls, whereas dasatinib treatment
resulted in complete regression of CNS tumors followed by tumor
stasis while animals were on therapy. Antitumor activity, as
determined by BLI, also correlated with increased survival. In
contrast to imatinib, dasatinib had a significant effect on survival
(P  .05 vs untreated control; Table 1).
Experiment 3. To further delineate the effects of dasatinib,
K562-pLUC#2 cells were implanted and allowed to grow to
well-established intracranial lesions. Dasatinib was then initiated at
escalated doses of 25 or 50 mg/kg once daily for 30 days. Both
dosages of dasatinib were associated with a significant increase in
survival (P  .001 vs untreated control; Table 1). Furthermore,
BLI indicated that intracranial tumors regressed to near nondetect-
able levels and remained so as long as the animals were on
treatment (Figures 1A,B and 2). Once drug administration stopped,
all animals redeveloped intracranial tumors and eventually died.
To rationalize the robust antitumor activity of dasatinib in these
intracranial CML models, we assessed the plasma and brain
concentrations of dasatinib. Dasatinib brain concentrations were,
on average, 12- to 31-fold lower than in plasma (ie, brain/plasma
ratio or brain penetrance of 3.2%-8.6%). But significantly, dasat-
inib pharmacokinetic analysis demonstrated that it readily achieved
brain concentrations required to achieve 50% inhibition of cellular
proliferation of K562 cells in vitro (0.5 nM). For example, a daily
dose of dasatinib 50 mg/kg was associated with brain concentra-
tions of 10 to 100 nM for nearly 24 hours (Figure 1C). This level of
CNS penetration, based on this calculation, was sufficient to
produce the antitumor activity observed in this study.
Clinical effects of dasatinib in CNS manifestations of
Ph leukemia
To investigate the potential clinical effects of dasatinib on CNS
leukemia, we collected data from 14 patients with imatinib-
resistant or -intolerant BC-CML or Ph ALL and CNS involve-
ment. Ten patients were enrolled in dasatinib clinical studies,
whereas 4 patients received dasatinib for compassionate use. Of
Table 1. Antitumor activity of dasatinib and imatinib in intracranial CML models
Tumor (study no.),
compound Dose, mg/kg
Route; schedule;
day treatment started
Efficacy (n  10)
Tolerability, AWC, gMST, days %T/C
K562 (1)
Dasatinib 15 Orally; BID  40; 5 49.5* 450† ND
Dasatinib 5 Orally; BID  26; 5 29.5 268† ND
Imatinib 100 Orally; BID  10; 5 11.0 100 ND
Control — 11.0 — ND
K562-pLUC#2 (2)
Dasatinib 15 Orally; BID  14; 6 76.0 267‡ 1.1
Imatinib 100 Orally; BID  14; 6 35.0 123 1.5
Control — 28.5 — 1.3
K562-pLUC#2 (3)
Dasatinib 50 Orally; QD  30; 9 61.5 256§ 0.3
Dasatinib 25 Orally; QD  30; 9 55.0 229§ 0.1
Control — 24.0 — ND
MST indicates median survival time; %T/C, (MST treated/MST control)  100; AWC, average weight change; BID, twice daily; QD, once daily; ND, not determined; and —,
not applicable.
*Two of 10 animals survived with no evidence of disease at the end of study (day 109).
†P  .01 versus untreated control.
‡P  .05 versus untreated control.
§P .001 versus untreated control.
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these, 11 were treated with dasatinib as a first-line therapy for CNS
leukemia, whereas 3 patients experienced a CNS relapse while on
dasatinib therapy administered for other clinical reasons. Patient
characteristics are described in Table 2, and treatment regimens are
described in Table 3. Five patients received concomitant intrathecal
therapy to treat CNS disease. The clinical course of an index patient
with massive CNS involvement and dasatinib monotherapy is
shown in Figure 3.
All of the 11 clinically evaluable patients responded to dasatinib
(Table 3). Complete responses, defined as either disappearance of
leukemic blasts from CSF or radiologic findings in magnetic
resonance imaging, were observed in 7 patients. Four of these were
achieved with dasatinib monotherapy. Of the 3 patients achieving a
partial response, one had a very good partial response and
2 patients had long-lasting, clinically meaningful responses to
dasatinib. One patient (patient 6) was only evaluated clinically for
CNS disease and was considered to be stable at 22 months.
CNS responses to dasatinib were generally durable and were
maintained for at least 6 months in 5 patients and for at least
12 months in 2 patients. Responses were maintained for at least
3 months in 9 evaluable patients.
To assess mechanisms of dasatinib resistance for CNS leuke-
mia, we collected data from 3 additional patients who experienced
a CNS relapse while on dasatinib. BCR-ABL kinase domain
sequencing from leukemic blast cells in CSF showed point
mutations (T315I and V299L) in 2 patients conferring absolute
resistance to dasatinib (no sequencing data available from one
patient). Thus, CSF relapse was most likely attributed to selection
of a dasatinib-resistant clone, not because of poor penetration of
dasatinib into the CSF.
Dasatinib concentrations in CSF
CSF pharmacokinetic samples were obtained from a different
group of patients: 15 adult subjects with CML or Ph ALL and
7 pediatric subjects with Ph ALL participating in dasatinib trials.
The samples were collected approximately 3 hours after an oral
dasatinib dose. Of these, detectable levels of dasatinib were found
in only 2 of the adult patients (3.9 and 20.1 nM) and 4 of the
pediatric patients (1.4, 1.9, 2.3, and 2.7 nM). For 3 of the 6 samples
with detectable drug, CSF:plasma ratios could be determined (0.05,
0.08, and 0.28). Levels of 2 metabolites were below the limit of
quantification in all samples.
Discussion
We have shown here that dasatinib has antitumor effects in a mouse
model of intracranial CML and that these benefits can be trans-
ferred to the clinic with dasatinib inducing substantial responses in
patients with CNS Ph leukemia. In the mouse model, well-
established intracranial CML tumors regressed with dasatinib
treatment, significantly increasing animal survival. Moreover,
complete disease stabilization was achieved for as long as animals
were on dasatinib treatment. Hence, prolonged and continuous
administration of this agent may be necessary to effectively control
intracranial CML disease. Imatinib failed to show any activity in
these tumor models, correlating with several clinical and preclini-
cal findings.1,5,6,8,23 In addition to BCR-ABL, other mechanisms
may be responsible for extramedullary disease expansion, includ-
ing activation of Src family kinases.24-26 As well as its potent
inhibitory effects on BCR-ABL, dasatinib also inhibits Src family
Figure 1. Comparative in vivo antitumor activity of dasatinib and imatinib in the
intracranial K562-pLUC#2 CML model and plasma/brain pharmacokinetic pro-
file of dasatinib. (A) Tumor growth inhibition by dasatinib or imatinib in the K562-pLUC#2
intracranial model as determined by BLI. Treatment was initiated on day 6 after tumor cell
implantation. x indicates days of dasatinib administration. Mean photon emission plus or
minus SE for each treatment set is shown (n 8-9 mice per set). (B) Regression of large,
well-established intracranial K562-pLUC#2 tumors by dasatinib treatment as determined
by BLI (study 3). Treatment was initiated on day 9 after tumor cell implantation. x indicates
days of drug treatment. Mean photon emission plus or minus SE for each treatment set is
shown (n 8 mice per set). (C) Plasma and brain pharmacokinetic profile for dasatinib.
Each data point on the graph represents the average of 3 mice. Mice were killed at the
indicated time, and plasma was prepared from whole blood obtained by cardiac puncture;
brain biopsies were obtained from the same animals matching the plasma samples.
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proteins,27 which may underlie the preclinical and clinical activity
of dasatinib observed in our report.
During the absorptive phase (1-4 hours after dose), dasatinib
concentrations in the brain were on average 5.5% of those found in
the plasma (range, 3.2%-8.6%) in mice. In the 3 patients for whom
plasma and CSF concentrations were available, the brain pen-
etrance was 5%, 8%, and 28%, respectively. This CNS penetration
is considerably higher than that achieved by imatinib in several
preclinical and clinical reports (brain penetrance ranging from
0.5% to 2%).1,2,5,6,8 It should be noted that the CNS penetrance of
dasatinib is still low compared with other agents known to have
good penetration of the blood-brain barrier, such as cytarabine.28
The extent to which increased blood-brain barrier penetrance by
dasatinib versus imatinib is responsible for the apparent superior
CNS antitumor effects of dasatinib is unclear. However, it is
probable that other factors may also be important. For example, the
much greater potency (325-fold) of dasatinib over imatinib15 may
allow the achievement of a therapeutically effective concentration
of dasatinib because it has been shown to be active at low or
subnanomolar concentrations.15,16 This increased potency, along
with the fact that the CSF is a low-protein environment where
dasatinib is likely to exist as a free drug, suggests that even if
dasatinib levels in the CNS are relatively low, the dasatinib
concentrations achieved are sufficient for antitumor activity. The
concentrations of dasatinib found in the CSF of patients (range,
1.4-20.1 nM) are consistent with the observed antitumor activity in
the CNS. However, further studies are needed to determine the
relationship of dasatinib CNS pharmacokinetics and clinical re-
sponses in more detail.
In these patients with CNS Ph leukemia, dasatinib was
associated with substantial clinical responses. Our results confirm
those of a single case report concerning the effects of dasatinib in
CNS Ph leukemia.18 In the current study, clinically meaningful
responses were achieved with dasatinib even as monotherapy and
were maintained for more than or equal to 6 months in 45% of
patients. Our data compare favorably with results from high-dose
Figure 2. Dasatinib induced regression of well-
established intracranial K562-pLUC#2 tumors in
vivo. On day 9 after tumor implantation, animals with
similarly well-established intracranial tumors were ran-
domized into treatment and control sets (n  8 mice
per set) and baseline images were taken (A,C,E). Mice
were then treated orally with either 50 or 25 mg/kg of
dasatinib daily for 30 consecutive days. On day 20 after
tumor implantation, a second set of bioluminescence
images were taken (B,D,F). (A,B) Dasatinib treatment,
50 mg/kg. (C,D) Dasatinib treatment, 25 mg/kg.
(E,F) Untreated control. Images were set at the same
pseudo-color scale to show relative bioluminescent
changes over time and signal intensity differences
between treatment groups. Dasatinib treatment re-
sulted in complete regression of intracranial tumors to
near nondetectable levels, whereas untreated control
showed progressive tumor growth with 2 of 8 animals
dead on day 20 after tumor implant.
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cytarabine.29 Furthermore, the toxicity profile of oral dasatinib is
superior to intensive intravenous chemotherapy.
In bone marrow Ph leukemia, the most common mechanisms for
dasatinib resistance are acquired BCR-ABL point domain mutations in
the gatekeeper position of the kinase (V299L, T315I, F317L). Of the
3 patients who experienced a CNS relapse on dasatinib, BCR-ABL
kinase domain mutation data from leukemic blasts in CSF was obtained
for 2 patients. Both these patients showed selection of a dasatinib-
resistant leukemic clone in the CSF (V299L, T315I), which had caused
disease relapse. This suggests a strong selection pressure exerted by
dasatinib and thus access of the drug into the CSF.
Although chronic phase CML is derived from a malignant stem
cell, the leukemia-initiating mutations in Ph ALL30 and CML in
blastic phase31 arise from a more committed progenitor. During
dasatinib therapy, CNS relapse and expansion of a mutated clone in
the CSF, but not in bone marrow, suggest that the origin of CNS
leukemia is from a leukemic stem cell homing to CNS at the time of
diagnosis. Theoretically, the CNS-specific homing of this leukemic
stem cell prevents it from expanding outside of CNS. Interestingly,
the CNS clone may be in a dormant state for many years as the time
from diagnosis to CNS relapse in some of our patients was up to
8 years. Recent data indicate that cell surface receptors on leukemic
Table 2. Patient and disease characteristics
Patient
no. Sex Age, y Disease
Prior
SCT CNS relapse site
Isolated CNS relapse
(systemic disease status)
Dasatinib as first-line
therapy for
CNS disease
Enrolled into
dasatinib clinical
trials
1 Male 66 Ph ALL No CSF No Yes Yes
2 Male 41 Ly-BC-CML Yes CSF Yes (stable MRD) Yes No*
3 Male 7 Ph ALL Yes CSF Yes (stable MRD) Yes Yes
4 Male 13 Ph ALL Yes (2) CSF No Yes Yes
5 Female 59 BC-CML Yes Brain tumor (MRI) Yes (CP) Yes No*
6 Male 41 My-BC-CML No Brain tumors (MRI) No Yes Yes
7 Female 25 Ph ALL No CSF Yes (stable MRD) Yes Yes
8 Female 35 Ph ALL Yes CSF brain tumors (MRI) Yes (stable MRD) Yes Yes
9 Male 59 My-BC-CML Yes CSF Yes (stable MRD) Yes No*
10 Male 12 Ph ALL Yes CSF No Yes Yes
11 Male 10 Ph ALL Yes (2) CSF No Yes Yes
12 Male 49 Ph ALL Yes CSF Yes (stable MRD) No Yes
13 Male 79 My-BC-CML No CSF Yes (stable MRD) No Yes
14 Male 26 Ly-BC-CML No CSF Yes (CP) No No*
SCT indicates stem cell transplantation; CNS, central nervous system; PhALL, Philadelphia chromosome–positive acute lymphoblastic leukemia; Ly-BC-CML, lymphoid
blast crisis of CML; My-BC-CML, myeloid blast crisis of chronic myeloid leukemia; CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; MRD, minimal residual disease;
and CP, chronic phase.
*Enrolled in compassionate use programs.
Table 3. Dasatinib treatment and response in evaluable patients
Patient
no. Dasatinib dose
Dose
regimen
Dasatinib
treatment
duration, mo
Concurrent
intrathecal
therapy
Best
response
Response
duration, mo Therapy details
1 140 mg/day, reduced due to
toxicity to 50 mg  5
days/week at 8 months
BID 13 No CR 11 DXM at the beginning
2 140 mg/day BID 5 Yes CR 5 IT therapy prior to start of dasatinib with
poor results, received three IT
therapies* after dasatinib start
3 60 mg/m2 (25 days) then
80 mg/m2 per day
QD 10 No CR 6 IT therapy initiated at 6 months for
relapse
4 60 mg/m2 (29 days) then
80 mg/m2 per day
QD 4 No CR 3 IT therapy initiated at 3 months due to
systemic relapse
5 140 mg/day BID 3 No Radiologic CR 3 None
6 140 mg/day QD 22 No Clinical CR 22 DXM at the beginning
7 140 mg/day then 200 mg/day at
4 months
BID 21 No PR 6 IT therapy and later cranial radiation
when treatment was intensified after
6 months due to relapse
8 140 mg/day for 3 months,
varying dosing with long
interruptions, currently 50 mg
every other day
QD 26 Yes PR 26 DXM, IT therapy*†‡
9 140 mg/day BID 3 Yes VGPR 3 IT therapy*†
10 60 mg/m2 per day QD 1.8 Yes CR 1.5 Systemic steroids, IT therapy*†‡
11 80 (39 days), 120 (20 days)
then 160 mg/m2 per day
BID 2 Yes CR 2 IT therapy*
BID indicates twice daily; QD, once daily; CR, complete response; PR, partial response; VGPR, very good partial response; DXM, dexamethasone; and IT therapy,
intrathecal therapy.
*Cytarabine.
†Methotrexate.
‡Prednisolone.
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blasts, such as CXCR432 or CD44,33 are key determinants in
dissemination of leukemia to extramedullary sites. The exact
molecular mechanisms are still to be defined but probably involve
organ-specific “zip codes” on endothelial cells.34
In conclusion, dasatinib has promising therapeutic potential in
managing intracranial leukemic disease, and substantial clinical
activity in patients who experience CNS relapse while on imatinib
therapy. Dasatinib may prove to be a valuable alternative to
imatinib and an addendum to conventional cytotoxic therapy for
Ph CNS leukemia. Prospective, controlled studies are warranted
to more fully determine treatment responses and characterize drug
tolerability and safety in this patient population.
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